18F-Fluoroazomycin Arabinoside (18F-FAZA) in Lung Cancer

Last updated: July 12, 2024
Sponsor: University Health Network, Toronto
Overall Status: Active - Recruiting

Phase

N/A

Condition

Non-small Cell Lung Cancer

Lung Cancer

Lung Disease

Treatment

18-F-FAZA

Clinical Study ID

NCT02701699
UHN REB 13-6528-C
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to look for low levels of oxygen (hypoxia) in lung cancer using a positron emission tomography (PET) scan. Hypoxia can influence how lung cancer grows and responds to treatments like radiotherapy and chemotherapy. The use of PET scans to measure hypoxia may be better and simpler than the approaches used previously. This study will assess whether or not PET scans can provide useful information about hypoxia in lung cancer.

In this study, a radiotracer called Fluoroazomycin Arabinoside (FAZA) will be used to measure hypoxia in the patient's tumour. FAZA has already been used in many cancers including lung cancer. Patients who consent to participate in this trial will receive 1 FAZA PET Scan prior to their first radiotherapy treatment

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age ≥ 18 years

  2. Patients with stage II or III lung cancer (both NSCLC and SCLC) qualifying forradiotherapy to the primary tumor, with or without treatment of mediastinal or hilarlymph nodes

  3. Intention to treat using radiotherapy according to the current treatment policies ofthe PMH Lung Group

  4. Concurrent systemic therapy allowed

  5. A negative serum pregnancy test within the two week interval immediately prior toPET-CT imaging, in women of child-bearing age

  6. Ability to provide written informed consent to participate in the study

Exclusion

Exclusion Criteria:

  1. Previous radiotherapy to intended treatment volumes.

  2. Previous systemic therapy

  3. Active malignancy other than lung cancer

  4. Unable to remain supine for more than 60 minutes

  5. Pregnancy

  6. Age less than 18 years old

  7. Failure to provide written informed consent

Study Design

Total Participants: 20
Treatment Group(s): 1
Primary Treatment: 18-F-FAZA
Phase:
Study Start date:
December 01, 2014
Estimated Completion Date:
June 30, 2025

Connect with a study center

  • University Health Network, Princess Margaret Cancer Centre

    Toronto, Ontario M5G 2M9
    Canada

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.